Liso-cel Approved by FDA as Breyanzi
Late today, BMS announced US approval of liso-cel in r/r LBCL after >2L of systemic therapy. The press release states that the target turnaround time is 24 days from its manufacturing facility in Bothell, Washington, USA. The Celltelligence team will be conducting a full thoughts-on label review in the coming days (link to Breyanzi PI here).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.